5 stories mentioning CGEMUpdated 27d ago
Every FINWIRES story that references CGEM, newest first.
Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.
Cullinan Therapeutics (CGEM) has an average rating of buy and mean price target of $33.25, according to analysts polled by FactSet.Price: $20.17, Change: $-0.17, Percent Change: -0.82%
Healthcare stocks eased Thursday afternoon with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each dropping 0.2%.The iShares Biotechnology ETF (IBB) fell 0.6%.In corporate news, Novartis (NVS) defeated a bid by Accord Healthcare to invalidate its Entresto patent, with a UK court ruling that the patent and a related protection certificate remain valid, Reuters reported. Novartis shares declined 0.2%.MapLight Therapeutics (MPLT) shares climbed 4%. The company plans to sell securities in a private-placement financing for gross proceeds of $150 million.MeiraGTx (MGTX) shares rose 2.6% after the company reported a Q2 profit as revenue soared.Cullinan Therapeutics (CGEM), Taiho Oncology and Taiho Pharmaceutical said a phase 3 trial evaluating the combination of their jointly developed drug zipalertinib and chemotherapy to treat adults with non-small cell lung cancer met its primary endpoint. Cullinan shares rose 2.2%.
Healthcare stocks were advancing pre-bell Thursday, with the State Street Health Care Select Sector SPDR ETF (XLV) up 0.3% and the iShares Biotechnology ETF (IBB) 0.6% higher.MeiraGTx (MGTX) shares were up more than 7% after the company reported that it swung to a Q2 net income as revenue surged during the period.Cullinan Therapeutics (CGEM), Taiho Oncology and Taiho Pharmaceutical said a phase 3 clinical trial evaluating the combination of their jointly developed drug zipalertinib and chemotherapy as a first-line treatment for adults with previously untreated, locally advanced or metastatic non-small cell lung cancer met its primary endpoint of progression-free survival. Shares of Cullinan Therapeutics were up more than 7% premarket.Ascendis Pharma (ASND) stock was up more than 1% after the company posted higher Q2 non-IFRS earnings and revenue.
Cullinan Therapeutics (CGEM) has an average rating of buy and mean price target of $32.83, according to analysts polled by FactSet.Price: $17.46, Change: $-0.15, Percent Change: -0.85%
Healthcare stocks were leaning lower premarket Tuesday, with the State Street Health Care Select Sector SPDR ETF (XLV) slightly declining and the iShares Biotechnology ETF (IBB) down 0.3%.Relay Therapeutics (RLAY) shares were up more than 11% after the company said early phase 2 data showed its experimental drug zovegalisib reduced lesion volume in patients with rare vascular anomalies linked to PIK3CA mutations.Cullinan Therapeutics (CGEM) received the US Food and Drug Administration's orphan drug designation for its CLN-049 investigational therapy for the treatment of relapsed/refractory acute myeloid leukemia, the company said. Cullinan Therapeutics stock was up more than 2% pre-bell.Tiziana Life Sciences' (TLSA) intranasal foralumab showed good long-term tolerability and fatigue improvement in an expanded access program involving 14 patients with non-active secondary progressive multiple sclerosis based on updated clinical data, the biotechnology company said. Shares of Tiziana Life Sciences were up more than 2% premarket.
